Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 6.2% from a year ago
Cash & equivalents stood at $134.7M at the end of Q1 FY2026, up 6.2% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at -33.3% a year.
Context
- Cash & equivalents amounted to 17.8% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +6.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 155.46M USD
- Year-over-year change
- -17.8%
- 4-year CAGR
- +5.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 155.46M | -17.8% |
| FY2024 | 2024-12-31 | 189.18M | -16.6% |
| FY2023 | 2023-12-31 | 226.75M | -56.7% |
| FY2022 | 2022-12-31 | 523.51M | +324.2% |
| FY2021 | 2021-12-31 | 123.41M | — |
Cash & Equivalents vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's Mar 2026 cash & equivalents of $134.7M is the 4th highest of the 10 companies compared; the peer median is $83.8M.
- Its year-over-year change of +6.2% is the 3rd highest of 10, against a peer median of -12.8%.
- Cash & equivalents amounts to 17.8% of total assets for NTLA, versus a peer median of 17.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $219.83M | -22.1% | +8.2% | 15.9% | |
| Sep 2026 | $192.03M | -33.8% | +18.8% | 7.5% | |
| Mar 2026 | $139.99M | -35.6% | -29.4% | 18.0% | |
| Mar 2026 | $134.7M | +6.2% | -33.3% | 17.8% | |
| Mar 2026 | $123.65M | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $83.8M | -12.8% | -25.9% | 22.4% | |
| Mar 2026 | $71.54M | +7.5% | -17.1% | 29.2% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
| Jun 2026 | $16.33M | +18.7% | +83.9% | 9.6% | |
| Mar 2026 | $12.06M | -59.0% | -40.4% | 8.1% | |
| Peer median (excluding NTLA) | $83.8M | -12.8% | -17.1% | 17.4% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 123.41M | 523.51M | 226.75M | 189.18M | 155.46M |
| Short-term Investments | 625.28M | 669.12M | 685.48M | 412.33M | 294.42M |
| Net Receivables | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 20.41M | 49.65M | 29.83M | 68.36M |
| Total Current Assets | 769.3M | 1.22B | 998.33M | 639.86M | 527.71M |
| Property, Plant & Equipment (Net) | 100.11M | 161M | 148.14M | 246.67M | 123.63M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 425.05M | 142.32M | 154.51M | 44.26M | 35.54M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 260.22M | 155.25M |
| Total Non-current Assets | 525.16M | 303.32M | 302.65M | 551.15M | 314.42M |
| Total Assets | 1.29B | 1.52B | 1.3B | 1.19B | 842.13M |
| Account Payables | 9.65M | 5.15M | 7.45M | 14.59M | 20.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 63.76M | 43.84M | 22.14M | 20.66M | 7.29M |
| Other Current Liabilities | 20.36M | 21.78M | 6.89M | 24.08M | 23.07M |
| Total Current Liabilities | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M |
| Long-term Debt | 0 | 0 | 0 | 0 | 66.85M |
| Deferred Tax Liabilities | 0 | 0 | (38.85M) | 0 | 0 |
| Deferred Revenue (Non-current) | 63.48M | 19.93M | 38.85M | 18.26M | 0 |
| Other Non-current Liabilities | 0 | 24.03M | 38.85M | 0 | 0 |
| Total Non-current Liabilities | 128.39M | 157.98M | 135.6M | 208.21M | 66.85M |
| Total Liabilities | 254.22M | 284.53M | 250.81M | 319.06M | 170.73M |
| Common Stock | 7K | 9K | 9K | 10K | 12K |
| Retained Earnings | (703M) | (1.18B) | (1.66B) | (2.18B) | (2.59B) |
| Accumulated OCI | (2.63M) | (7.46M) | (2.26M) | 605K | 1.03M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M |
| Total Debt | 74.02M | 130.7M | 115.35M | 210.2M | 93.33M |
| Net Debt | (49.38M) | (392.8M) | (111.4M) | 21.02M | (62.14M) |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.